Tyrogenex Inc., a West Palm Beach, FL-based Xcovery Group company focused on discovering and developing novel patented cancer and ophthalmic therapeutics, received $15m in Series D financing.
The backer was Brace Pharma, the U.S. investment company of EMS S/A, the largest pharmaceutical company in Brazil. Vinzenz Ploerer, president and CEO of Brace Pharma, joined Tyrogenex’ Board of Directors.
Led by Sheridan G. Snyder, chairman and chief executive officer, and Dr. Chris Liang, executive vice president and chief scientific officer, Tyrogenex and its subsidiary, Xcovery Vision, are privately held companies focused on developing X-82, an orally administered, dual VEGFR/PDGFR inhibitor, as a targeted therapeutic for solid tumors and ophthalmological diseases, respectively.
The funding from the round will support further clinical development of X-82, including a phase 2, randomized study of X-82 as an oral treatment of wet age-related macular degeneration (AMD) that is expected to begin later this year.
FinSMEs
19/06/2014